UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2006 (November 17, 2006)
REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| New York | 000-19034 | 133444607 | ||
| (State or other jurisdiction of | (Commission File No.) | (IRS Employer Identification No.) | ||
| Incorporation) |
777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)
(Address of principal executive offices, including zip code)
(914) 347-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On November 17, 2006, Regeneron Pharmaceuticals, Inc. issued a press release announcing that
it had completed its public offering of 7,600,000 shares of common stock. A copy of this press
release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press Release dated November 17, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 20, 2006
|
REGENERON PHARMACEUTICALS, INC. | |||||
| By: | /s/ Stuart Kolinski
|
|||||
| Name: Stuart Kolinski | ||||||
| Title: Vice President and General Counsel | ||||||
Exhibit Index
| Number | Description | |
99.1
|
Press Release dated November 17, 2006. |
Exhibit 99.1
REGENERON ANNOUNCES CLOSING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK
Tarrytown, New York (November 17, 2006) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
announced that it has completed its public offering of 7,600,000 shares of common stock.
The proceeds of the offering received by Regeneron, totaling approximately $175 million before
expenses, will be used to fund pre-clinical and clinical development of our product candidates, to
fund basic research activities, to continue development of our technology platforms, for capital
expenditures, to redeem, repay or purchase our 5.5% convertible senior subordinated notes due
October 17, 2008, and for general corporate purposes, including working capital, acquisitions, and
other business opportunities
The offering was underwritten by Morgan Stanley & Co. Incorporated.
About Regeneron Pharmaceuticals
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize
therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic
candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory
diseases, and has preclinical programs in other diseases and disorders.
This news release discusses historical information and includes forward-looking statements
about Regeneron and its products, programs, finances, and business, all of which involve a number
of risks and uncertainties, such as risks associated with preclinical and clinical development of
our drug candidates, determinations by regulatory and administrative governmental authorities which
may delay or restrict our ability to continue to develop or commercialize our drug candidates,
competing drugs that are superior to our product candidates, unanticipated expenses, the
availability and cost of capital, the costs of developing, producing, and selling products, the
potential for any collaboration agreement, including our agreements with the sanofi-aventis Group
and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated
with third party intellectual property, and other material risks. A more complete description of
these and other material risks can be found in Regeneron’s filings with the United States
Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31,
2005 and Form 10-Q for the quarter ended September 30, 2006. Regeneron does not undertake any
obligation to update publicly any forward-looking statement, whether as a result of new
information, future events, or otherwise unless required by law.
###
Contacts: |
||
Investors:
|
Media: | |
Charles Poole
|
Kimberly Chen | |
914.345.7640
|
212.845.5634 | |
Charles.Poole@regeneron.com
|
Kchen@biosector2.com |